CHDs occasionally have coronary complications; however, stent implantation is technically difficult in small children. We reported a successful drug-eluting stent implantation into the congenital anomalous coronary artery in a 6-year-old boy. This treatment is useful for rescuing coronary stenosis, and dual antiplatelet therapy is important to prevent stent restenosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1047951118002512 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endo-Bentall Repair: Early Results and Feasibility of a Physician-Constructed Endo-Bentall Device.
J Thorac Cardiovasc Surg
January 2025
Department of Surgery, Division of Vascular Surgery, University of Maryland School of Medicine.
Objective: We present our experience with endovascular Bentall procedure (Endo-Bentall) using a modular valve conduit (Endo-Bentall) in high-risk patients with aortic root pathologies.
Methods: The physician constructed Endo-Bentall device is composed of a self-expanding transcatheter aortic valve (TAVR), aortic endovascular stent graft (TEVAR), and two wire-reinforced fenestrations for coronary artery stenting. The TAVR valve is sutured into an appropriately sized TEVAR graft.
Novel Endovascular Technique for Thrombus Removal: The "Super Grab a Clot and Hold ON (Super GACHON)" Technique.
Case Rep Cardiol
January 2025
Department of Cardiology, Toyohashi Heart Center, Toyohashi, Aichi, Japan.
We present a case of a 60-year-old man with claudication in his right foot; the patient had received stent-graft implantation for the right superficial femoral artery (SFA) 1 year ago. Computed tomography angiography suggested stent occlusion of the right SFA, and a thrombus was considered to cause occlusion. To avoid distal embolization, we performed lesion recanalization via a trans-ankle intervention.
View Article and Find Full Text PDFImpact of procedural and patient-related risks on 1-year outcomes for patients treated with 1-month dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy after biodegradable-polymer drug-eluting stent implantation.
Cardiovasc Interv Ther
January 2025
Department of Internal Medicine, Division of Cardiology, Iwate Medical University, 2-1-1 Idaidori, Yahaba-Cho, Shiwa-Gun, Iwate, 028-3695, Japan.
In clinical practice, the impact of procedural or patient-related risk factors on 1-year clinical outcomes in patients receiving 1-month of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy after contemporary percutaneous coronary intervention (PCI) remains unclear. Using data from the multi-center REIWA registry which included patients treated with thin-strut biodegradable polymer drug-eluting stent (BP-DES) and 1-month DAPT followed by P2Y12 inhibitor monotherapy, we assessed the primary endpoint (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, ischemic or hemorrhagic stroke, and major or minor bleeding) in patients with and without procedural (treatment of three vessels, three or more lesions, three or more stents, bifurcation with two stents, long stenting, and target of chronic total occlusion) and patient-related risk factor (renal insufficiency, anemia, peripheral vascular disease, prior or current history of heart failure and advanced age of ≥ 75 years). Among the 1,202 patients who underwent complete revascularization by PCI, 276 (23.
View Article and Find Full Text PDFPercutaneous self-expandable valve implantation in patients with stented pulmonary arteries: case examples.
Cardiol Young
January 2025
Department of Paediatric Cardiology, University Children's Hospital, Jagiellonian University Medical College, Krakow, Poland.
CHDs affecting the right ventricular outflow tract often require repeated surgical or transcatheter interventions due to pulmonary insufficiency or stenosis. This study presents percutaneous implantation of large self-expanding valves in patients with complex right ventricular outflow tract anatomy after prior pulmonary branch stenting.
View Article and Find Full Text PDFPulmonary vein stenosis (PVS) is an insidious diagnosis associated with morbidity and mortality. Pharmacologic therapy may suffice initially, but advanced stages demand mechanical intervention. Pulmonary stent implantation (PSI) and pulmonary balloon angioplasty (PBA) are common strategies, both carrying restenosis risks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!